KRAS and lung cancer: A large scale phase III clinical trial (Galaxy-2) in advanced lung cancer evaluated the effects of combining ganetespib and anti-microtubule agent docetaxel in either KRAS mutant or KRAS wild type non-small cell lung cancer (NSCLC) patients.